Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04028388Phase 2Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Role: lead

NCT05242926Phase 1Withdrawn

Absorption and Excretion of Oral Docetaxel

Role: lead

NCT03136640Phase 1Completed

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT05084456Phase 1Withdrawn

Oral Docetaxel in Patients With Normal or Impaired Liver Function

Role: lead

NCT03150368Phase 1Completed

Extended Use of ModraDoc006/r

Role: lead

NCT03147378Phase 1Completed

Food Effect Study of ModraDoc006 in Combination With Ritonavir

Role: lead

NCT03890744Phase 2Completed

ModraDoc006/r in Patients With Breast Cancer

Role: lead

All 7 trials loaded